Although Ab peptides are causative agents in Alzheimer's disease (AD), the underlying mechanisms are still elusive. We report that Ab42 induces a translational block by activating AMPK, thereby inhibiting the mTOR pathway. This translational block leads to widespread ER stress, which activates JNK3. JNK3 in turn phosphorylates APP at T668, thereby facilitating its endocytosis and subsequent processing. In support, pharmacologically blocking translation results in a significant increase in Ab42 in a JNK3-dependent manner. Thus, JNK3 activation, which is increased in human AD cases and a familial AD (FAD) mouse model, is integral to perpetuating Ab42 production. Concomitantly, deletion of JNK3 from FAD mice results in a dramatic reduction in Ab42 levels and overall plaque loads and increased neuronal number and improved cognition. This reveals AD as a metabolic disease that is under tight control by JNK3.
INTRODUCTION
Ab peptide accumulation is a hallmark of Alzheimer's disease (AD), being released from neurons via extracellular and subsequent intramembrane cleavage reactions of the amyloid precursor protein (APP) (Tanzi and Bertram, 2005) . Recent findings suggest that soluble oligomeric are the pathogenic forms, eliciting neurotoxic effects that culminate in synaptic dysfunction and neuronal loss (Haass and Selkoe, 2007) . Discovery of Prp and EphB2 as receptors for oligomeric Ab42 (Cissé et al., 2011; Lauré n et al., 2009) provides support for the view that oligomeric Ab peptides could function as neurotoxic ligands, initiating diverse cellular signaling events that range widely, including inflammation, mitochondrial dysfunction, oxidative stress, apoptosis/autophagy, intracellular calcium imbalance, and a block in LTP (Koo and Kopan, 2004) , any of which could contribute to AD pathology. The mechanism by which oligomeric Ab peptides elicit such diverse cellular outcomes, however, has remained elusive.
Here, we report that oligomeric Ab42 exerts such diverse effects in part by inducing a translational block, which is accompanied by ER stress as indicated by increased phosphorylation of Eif2a in hippocampal neurons. Increased Eif2a phosphorylation was reported to inhibit the late phase of LTP and memory acquisition (Costa-Mattioli et al., 2007 . Once induced, ER stress activates Unfolded Protein Response (UPR), inducing widespread secondary reactions, some of which include changes in inflammatory responses as well as cell survival programs (Ron and Walter, 2007) , the often reported phenotypes in AD.
As part of UPR, ER stress activates the JNK pathway (Urano et al., 2000) . JNK proteins, especially JNK3, a brain-specific JNK isoform, have been reported to play roles under neurodegenerative conditions, such as Parkinson's disease: deletion of JNK3 in combination with JNK2 prevented loss of dopaminergic neurons after MPTP administration (Hunot et al., 2004) . Deleting JNK3 also resulted in a significant increase in neuronal and oliogodendrocyte survival after traumatic injuries in the CNS (Beffert et al., 2006; Li et al., 2007) . Although JNK activation has been reported in human AD brains, its role in AD pathology development remained unclear. To address this question, we analyzed an AD mouse model with and without JNK3. Our results indicate that JNK3 activation is integral to AD pathology, where JNK3 deletion restores the translational block induced by oligomeric Ab42 and the effect of UPR.
RESULTS
Oligomeric Ab42 Induces a Translational Block by Activating AMPK, Thereby Inhibiting the mTOR Pathway Oligomeric Ab42 inhibits LTP and impairs memory formation in vivo (Cleary et al., 2005; Walsh et al., 2002) , suggesting that Ab peptides are pathogenic species that disrupt normal synaptic function and cognition. Disrupting translational control by disabling eif2a phosphorylation or deleting its kinase, GCN2, also resulted in inhibition of LTP and memory acquisition After propidium iodide incorporation while they were alive, cells were fixed and immunostained for MAP2 to identify neurons. (E) Oligomeric Ab42 induces a translational block by activating AMPK, thereby inhibiting the mTOR pathway. Rat hippocampal neurons were treated with 250 nM oligomeric Ab42, 0.5 mM Thapsigargin, and 10 nM Rapamycin for the indicated periods of time. Note that S792 phosphorylation in Raptor and S1387 phosphorylation in TSC2, both of which are phosphorylated by AMPK, were also increased. S6K phosphorylation declined gradually with oligomeric Ab42, suggesting mTOR inhibition. Oligomeric Ab42 also induces ER stress based on Eif2a phosphorylation. (Costa-Mattioli et al., 2005 . Considering these parallel findings, we decided to ask whether Ab42 could induce a translational block. To address the question, we measured the amount of 35 S-methionine incorporation in rat hippocampal neurons after treatment with 5 mM Ab42 overnight. It should be noted that the actual concentration of oligomeric Ab42 in 5 mM Ab42 was estimated to be 250 nM ( Figure 1A ). As controls, parallel cultures were treated with Cycloheximide, a protein synthesis inhibitor, and Rapamycin and Thapsigargin, agents whose actions impinge on the translational machinery. Oligomeric Ab42 treatment at 250 nM inhibited 35 S-methionine incorporation by 44% (n = 3-5, p % 0.0001), while 10 nM Rapamycin and 0.5 mM Thapsigargin reduced 35 S-methionine incorporation by 70%-72% (n = 3-5, p % 0.01 and 0.001, respectively, Figures  1B and 1C) . The effect of 20 mM Cycloheximide was virtually complete, blocking translation by 99% (n = 3-5, p % 0.00001).
The reduction in 35 S-methionine incorporation was not due to cell death induced by Ab42, since there were very few MAP2 + neurons that incorporated propidium iodide when alive (Figure 1D ). We therefore conclude that Ab42 induces a translational block in cultured neurons.
Rapamycin inhibits translation by blocking recruitment of mTOR to the translational initiation complex (Ma and Blenis, 2009) and Thapsigargin by inducing ER stress, which results in phosphorylation of Eif2a (Costa-Mattioli et al., 2009; Ron and Walter, 2007) . In order to understand whether the mechanism by which oligomeric Ab42 causes a translational block resembles that of Thapsigargin or Rapamycin, we examined the temporal changes in the phosphorylation status of various proteins that are known to be involved in the mTOR pathway and UPR in hippocampal neurons. Oligomeric Ab42 induced a rapid increase in AMP-activated protein kinase a (AMPKa) phosphorylation ( Figure 1E ). Rapamycin and Thapsigargin also activated AMPK, but the kinetics of its activation differed from that by oligomeric Ab42. Monomeric and fibrillar forms of Ab42 did not activate AMPK in hippocampal neurons ( Figure 1F ). AMPK was shown to phosphorylate TSC2 and Raptor at S1387 and S792, respectively, thereby inhibiting the mTOR pathway (Gwinn et al., 2008; Inoki et al., 2003) . Indeed, both TSC2 and Raptor were phosphorylated by oligomeric Ab42 in kinetics similar to that of AMPK phosphorylation, and phosphorylation of S6 kinase decreased gradually over time ( Figure 1E ). We hypothesized that oligomeric Ab42 inhibits the mTOR pathway in part by activating AMPK. Indeed, when AMPK activation was inhibited with 5 mM Compound C as indicated by a reduction in phospho-Raptor S792 levels, S6K phosphorylation was increased significantly with oligomeric Ab42 at all the time points tested ( Figure 1G ). These results together suggest that oligomeric Ab42 initiates a translational block by inhibiting the mTOR pathway via a mechanism that involves AMPK activation. It should also be noted that oligomeric Ab42 increased phosphorylation of Eif2a, although the extent of its increase is much less than that by Thapsigargin ( Figure 1E ). We interpret this result as suggesting that oligomeric Ab42-mediated translational block leads to UPR.
JNK3-Dependent Phosphorylation of APP Increases APP Endocytosis and Processing UPR was shown to activate the JNK pathway (Urano et al., 2000) . We hypothesized that once UPR is induced, it activates JNK3, which in turn promotes further APP processing by phosphorylating it at T668P in neurons. Indeed, Thapsigargin and Rapamycin induced JNK3 activity in rat hippocampal neurons: JNK3 activity increased 5-30 min after treatments, which was sustained for up to 3 hr (Figures 2A and 2B ). APP has a MAP kinase phosphorylation site at T668P, which becomes phosphorylated only in neurons (Iijima et al., 2000) . We hypothesized that JNK3-mediated phosphorylation of APP results in internalization of APP into endosomal compartments, wherein it undergoes amyloidogenic processing. In support, Ab42 has been detected in endosomes via immuno-EM in AD cases (Takahashi et al., 2002) . We first asked whether JNK3 phosphorylated T668P in vitro. Active JNK3 indeed phosphorylated APP at T668P in vitro, as JNK3 failed to phosphorylate APP when T668 was mutated to A668 ( Figure 2C ). Active CDK5/p35 complex, on the other hand, still phosphorylated the mutant APP A668 , suggesting that JNK3 phosphorylates T668P, while CDK5/p35 phosphorylates sites other than T668P.
As a way to address whether JNK activation affects APP internalization, we asked whether JNK activation alters the amount of the full-length APP on the cell surface. In addition, since Anisomycin activates p38 besides JNK, cortical neurons were preincubated for 1 hr with 1 mM cell-permeable JNKInteracting-Protein (JIP) peptides that inhibit JNK specifically (Barr et al., 2002; Farías et al., 2009) , while control cultures were treated with cell-permeable control peptides. JIP peptides, TAT-TI-JIP, contain 22-amino acids, which were shown to be necessary for JIP to inhibit JNK activation (Dickens et al., 1997) . The JIP peptides were also modified to make it permeable to mammalian cells by adding 10 amino acid sequences of HIV-TAT protein (Bonny et al., 2001; Schwarze et al., 1999) . After treatments with 50 ng/ml Anisomycin at 37 C for 0, 5, 15, and 30 min, cells were subjected to cell-surface biotinylation on ice for 30 min, and the amount of the cell-surface-located, biotinylated, full-length APP was determined following Neutravidin pulldown and subsequent western blotting for APP. In control cultures, Anisomycin treatment resulted in a rapid increase in biotinylated APP on the cell surface, which was followed by a gradual reduction in the amount of cell-surface biotinylated APP, reaching 52% of the original APP level by 30 min ( Figures  2D and 2E ). In contrast, when the endogenous JNK was inhibited by the JIP peptides as evidenced by the reduction in phosphocjun levels, cell-surface biotinylated APP levels remained unchanged ( Figures 2D and 2E ). Anisomycin treatment also (F) Monomeric and fibrillar forms of Ab42 fail to activate AMPK significantly. Rat hippocampal neurons were treated with 250 nM monomeric and fibrillar Ab42 for the indicated periods of time. (G) AMPK is necessary for oligomeric Ab42 to inhibit the mTOR pathway. S6K phosphorylation was increased with Ab42 when AMPK activation was inhibited by Compound C. Hippocampal neurons were treated with vehicle or 5 mM Compound C for 30 min prior to oligomeric Ab42 addition for the indicated amount of time. As a control for Compound C, p-Raptor S792 blot is also shown along with total S6K and Raptor protein blots.
increased the extent of APP phosphorylation at T668 in control cultures, while it did not in cultures treated with JIP peptides. These results suggest that JNK activation induces rapid trafficking of APP to the cell surface and subsequent internalization in part by phosphorylating APP at T668.
In order to test whether a JNK-mediated increase in internalization results in greater APP processing, cortical neurons were subjected to cell-surface biotinylation using a reversible biotin crosslinker, Sulfo-NHS-SS-Biotin, prior to treating them for 2 hr with Anisomycin and also inducing internalization at 37 C. At (C) JNK3 phosphorylates APP at T668P in vitro. Purified GST-APP ICD proteins were subjected to in vitro kinase assays in the presence of 32P-g-ATP using active JNK3, p38, CDK5/p35, and GSK-3b according to the manufacturer's instructions (Millipore). Only JNK3 and CDK5 phosphorylated APP, while p38 and GSK-3b did not. Note that JNK3 failed to phosphorylate APP, when T668 was mutated to A, but CDK5/p35-dependent phosphorylation still remained. These data suggest that JNK3 phosphorylates T668P, while CDK5/p35 phosphorylates sites other than T668P.
(D) JNK facilitates internalization of APP from the cell surface. For activation of the endogenous JNK pathway, hippocampal neurons were treated with 50 ng/ml Anisomycin for the indicated amount of time. After Anisomycin treatment, cells were subjected to cell-surface biotinylation on ice, and the biotinylated APP on the cell surface was detected following Neutravidin pulldown. Note that the amount of APP on the cell surface was increased initially, which was followed by a decrease with Anisomycin treatment over time. To test whether the changes in APP trafficking were due to JNK activation, a parallel set of cultures were treated with cell-permeable JNK inhibitor, TAT-TI-JIP peptides. Control cultures were treated with cell-permeable control peptides. When JNK activation was inhibited as indicated by the reduction in p-cjun and p-APP T668 levels, the amount of APP on the cell surface remained the same with Anisomycin treatment over time. These results suggest that JNK activation is necessary for inducing APP internalization.
(E) Quantification of cell-surface biotinylated APP after Anisomycin treatment. Data are represented as means ± SEM. p values were calculated by Student's t test.
(F) JNK activation increased APP processing following internalization. The amount of CTF increased with Anisomycin treatment. Following cell-surface biotinylation on ice, neurons were incubated with Anisomycin for 2 hr at 37 C. At the end of incubation, biotins left on the cell surface were removed by treating cells with 50 mM DTT before protein extracts were prepared. The internalized APP and its products were subsequently detected by Neutravidin pulldown followed by APP western blotting as well as 6E10 immunoprecipitation followed by Strepavidin-HRP blotting.
(G) T668P phosphorylation is necessary for APP internalization and processing. Anisomycin treatment reduced the full-length, biotinylated wild-type APP from the cell surface, while it increased the amount of biotinylated CTF. On the other hand, Anisomycin failed to induce internalization of and CTF production from the A668P mutant. 293T cells were transfected with the wild-type, full-length APP, and A668P mutant and subjected to the same cell-surface biotinylation and internalization as with cortical neurons. Also shown are p-JNK and JNK blots in addition to a loading control, ERK blots.
(H) Quantification of the data in (G). Data are represented as means ± SEM. p values were calculated by Student's t test.
the end of the incubation time, remaining biotins on cell-surface proteins were removed by treating cells with 50 mM DTT on ice, thus allowing selective detection of the internalized, cell-surface biotinylated proteins via Neutravidin pulldown/APP blotting or Streptavidin-conjugated secondary antibody after immunoprecipitation with 6E10 ( Figure 2F , Yu et al., 2011) . Anisomycin treatment increased the amount of biotinylated C-terminal fragment (CTF) production significantly, which correlated with increased T668 phosphorylation on CTF ( Figure 2F ). These results together suggest that JNK activation rapidly induces APP internalization/ endocytosis, thereby facilitating APP cleavage reactions. We next determined whether T668P phosphorylation by JNK is required for the internalization and processing of APP. For this, the full-length APP and a point mutant, A668, were transfected into 293T cells and subjected to cell-surface biotinylation and internalization assays as described above. The amount of the full-length APP that was biotinylated on the cell surface decreased with 30 min Anisomycin treatment in the wild-type, but not in the A668P mutant, suggesting that phosphorylation of T668P facilitates the internalization of the full-length receptor ( Figures 2G and 2H ). Upon internalization, a greater amount of biotinylated CTF was detected with the wild-type APP after Anisomycin treatment, but not with the A668P mutant (Figure 2G) . These results together suggest that T668P phosphorylation by JNK is necessary for APP to be internalized into endosomes and processed to generate Ab peptides.
JNK3 Activity Is Increased in Human AD Cases as well as in FAD Mice
Since our in vitro data suggested that JNK-dependent phosphorylation of T668P in APP is necessary for APP internalization and processing, we wished to determine the role of JNK3 in AD pathology by deleting JNK3 from an AD mouse model. We focused on JNK3, since unlike JNK1 and 2, JNK3 is enriched in the nervous system and plays a role under pathological conditions but has little effect on normal development (Kuan et al., 1999; Yang et al., 1997) . As our first step toward addressing the question, we asked whether JNK3 activity increased in human AD cases as well as in 5XFAD (henceforth called ''FAD'') mice in comparison to normal human and mice cases, respectively, by performing immunoprecipitation/kinase assays using JNK3-specific antibody. The specificity of JNK3 antibody has been demonstrated (Li et al., 2007) . FAD mice express mutant human APP (Swe/Fl/Lon) and PS1 (M146L/L286V) genes, each under a neuronal Thy1 promoter, producing more Ab42 than Ab40 (Oakley et al., 2006) . Indeed, JNK3 activity increased by 34% in human AD compared to normal cases (n = 9-13, p % 0.05), and by 27% in FAD:JNK3 +/+ mice compared to normal JNK3 +/+ mice at 5-6 months (n = 4, p % 0.05; Figures 3A-3D ). These results suggest that JNK3 activity correlates with AD pathology.
JNK3 Is the Principle JNK Isoform Activated in FAD Mice
We next determined where active JNK is localized in FAD brains using active JNK or p-JNK antibody in immunohistochemistry. Beginning at 2-3 months, the time when plaques begin to appear in FAD:JNK3 +/+ mice, p-JNK signals were predominantly detected near plaque structures, colocalizing with 8E5 immunoreactivity ( Figures 4A, 4B , and 4D), a dystrophic neurite marker (Games et al., 1995) . p-JNK signals were similarly reported to colocalize with 6E10 immunoreactivity in Tg2576/PS1 M146L mice (Braithwaite et al., 2010) . Also in aged monkey, p-JNK signals were detected near plaque structures ( Figure 4C ), suggesting that accumulation of active JNK near plaque structures is a common feature in primates as well. Figure 4D ): at 6 months, p-JNK signals are rarely detected in the soma. This result suggests that JNK3 becomes activated in damaged and degenerating neuritic processes, in agreement with previous reports (Abe et al., 2009; Cavalli et al., 2005; Muresan and Muresan, 2005) . It should be noted that JIP and JNK3 have been reported 
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Ab Activates AMPK to be transported along the axon under pathological conditions, presumably linking Kinesin-1 to receptor carrying vesicles, such as APP (Cavalli et al., 2005; Taru et al., 2002) . APP itself has been known to be transported along the axon via fast axonal transport (Koo et al., 1990) . We interpret these results as suggesting that JNK3 can potentially phosphorylate APP at T668P in the axon. Indeed, p-T668P signals were detected from damaged neurites in FAD:JNK3 +/+ mice ( Figure 4E ), similarly to p-JNK signals.
Unlike p-JNK signals, p-T668P signals were also prominent in cell bodies (data not shown). Together, these results suggest that JNK3 becomes activated in damaged and degenerating neuritic processes, where it can phosphorylate APP and regulate its processing. It should be noted that active JNK also colocalized with hyperphosphorylated tau in FAD:JNK3 +/+ mice (data not shown).
JNK3 Deletion Results in a Dramatic Reduction in Ab42 Levels and Plaque Loads in FAD Mice
We next analyzed the effect of deleting JNK3 on overall plaque deposition in FAD mice. In FAD:JNK3 À/À mice, insoluble Ab42 Figure 5A ). Soluble Ab40 and 42 levels were also reduced with JNK3 deletion (data not shown), but levels of soluble Ab peptides were negligible in FAD mice. Similar reductions were observed when the area occupied by plaques was quantified after 6E10 antibody labeling at 6 months (Figures 5B and 5C): 68% (n = 4, p % 0.01), 71% (n = 4, p % 0.01), and 65% (n = 4, p % 0.05) reductions were found in the frontal cortex, the subiculum, and the hippocampus, respectively. As evidenced by Thioflavin S staining ( Figure 5C ), the size and the number of plaques were also reduced in the frontal cortex and the hippocampus at 6 months by 58% (n = 4, p % 0.01) and 47% (n = 4, p % 0.01), respectively. Silver staining also indicated that JNK3 deletion resulted in a significant reduction in plaques throughout the brain at 6 months ( Figure 5D ). More importantly, the number of neurons in layers 5 and 6 of the frontal cortex was 17% higher in FAD:JNK3 À/À compared to that in FAD:JNK3 +/+ mice at 12-13 months, although it did not reach the levels found in non-FAD mice (n = 5-6; Figure 5E ). In line with these data, deletion of JNK3 from FAD mice resulted in a significant increase in long-term retention of fear memories at 12-13 months (n = 12; Figure 5F ). Similarly to NeuN data, the extent of improvement in cognitive function did not reach the normal levels found in non-FAD mice, although the difference was not statistically significant. Since modulation of associative plasticity in the amygdala where fear memories are encoded involves both the hippocampus and prefrontal cortex (Maren and Quirk, 2004), these results suggest that JNK3 activation affects cognitive function in FAD mice. Together, these results indicate that JNK3 plays a critical role in development of AD pathology by not only regulating Ab peptide production but also impacting neuronal survival and associative learning capacity in FAD mice.
We next asked whether JNK3 phosphorylates APP in the brain, thereby regulating b and/or g cleavage processes, by preparing whole-cell lysates as well as membrane fractions from 6-month-old mice. JNK3 indeed phosphorylates APP at T668P in FAD brains, without affecting the total APP protein levels ( Figure 5G ): while the human APP levels in whole-cell lysates were not very different between FAD:JNK3 +/+ and FAD:JNK3 À/À mice, p-T668P signals as well as human APP protein levels were significantly reduced when membrane fractions were analyzed ( Figure 5G ). It should be noted that sw192 antibody is specific to Swedish mutation in human APP (Haass et al., 1995) , thus it was used as a marker for FAD mice. In particular, p-T668P levels in membrane fractions were reduced to a much greater extent in a and b CTF than in the full-length APP with JNK3 deletion. This finding closely parallels the observation in human AD brains, wherein increased T668P phosphorylation mainly associated with a and b CTF and not the full-length APP (Lee et al., 2003) . In addition, total protein levels of a and b CTF were also reduced to a much greater extent than those in the full-length APP in the membrane fraction ( Figure 5G ). These results correlate faithfully with our Ab42 Elisa results at 6 months. We therefore interpret these results as suggesting that JNK3 phosphorylates APP preferentially in membranous compartments, such as vesicles/endosomes, thereby promoting APP processing. It should be noted that although BACE1 and PS1 levels were increased in FAD mice compared to those in normal mice as reported (O'Connor et al., 2008) , JNK3 deletion did not affect their levels greatly ( Figure 5H ). Similarly, neither the levels nor the extent of tau phosphorylation was altered by JNK3 deletion in FAD mice (data not shown). Figure 1 .
A Widespread Translational Block Is a Prominent

UPR Is a Prominent Feature in FAD Mice as well as in Human AD Cases
Oligomeric Ab42 treatment in hippocampal neurons also resulted in phosphorylation of Eif2a, albeit to a lower extent than that by Thapsigargin, suggesting that Ab42 induces ER stress ( Figure 1E ). A reduction in the global rate of translation is one of the earliest events in UPR, which leads to induction of a widespread secondary response that includes transcriptional activation of the target genes for UPR, namely, apoptotic as well as survival promoting genes (Ron and Walter, 2007) . Western blotting of a selected set of ER stress transducers, such as p-Eif2a, ATF4, and PERK, supported the finding that expression of these proteins was increased by approximately 2-fold in 3-month-old FAD:JNK3 +/+ compared to those in normal and FAD:JNK3 À/À mice (p < 0.05; Figures 7A and 7B ).
More importantly, cortical samples from five AD patients demonstrated a significant increase in ER stress markers, including p-Eif2a, ATF4, CHOP, and PERK compared to five age-matched control cases ( Figure 7C ). Together, these 
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Ab Activates AMPK suggest that the ER stress response occurs in human AD, and JNK3 activation may contribute to it.
JNK3 Activation Maintains a Positive Feedback Loop of Cyclic Ab42 Production
We hypothesized that once UPR is induced, it activates JNK3, which in turn promotes further APP processing by phosphorylating it at T668P. T668P phosphorylation facilitates increased internalization of the receptor into endosomal vesicles wherein APP undergoes processing to generate more Ab42. As the cycle repeats itself, more Ab42 accumulates, exacerbating the pathology ( Figure 8A ). To test the hypothesis that translational block and/or ER stress increases APP processing in a JNK3-dependent manner, organotypic slices were prepared from 8-to 10-week-old FAD:JNK3 +/+ and FAD:JNK3 À/À mice and treated with the vehicle, 0.5 mM Thapsigargin or 10 nM Rapamycin, for the indicated amounts of time. Both CTF and Ab peptide levels increased gradually over the 9 hr period in FAD:JNK3 +/+ slices with Thapsigargin as well as Rapamycin treatments ( Figure 8B ). These results suggest that ER stress or inhibiting the mTOR pathway is sufficient to induce Ab peptide production. Importantly, this increase in APP processing was dependent on JNK3, since the overall CTF and Ab peptide levels were significantly reduced in FAD:JNK3 À/À slices ( Figure 8B ). These results together indicate that JNK3 activation is necessary to perpetuate the cycle of translational block via mTOR, ER stress, JNK3 activation, and further production of Ab42.
DISCUSSION
Here, we report that JNK3 activation is critical for maintaining a positive feedback loop that culminates in continued production of Ab42. This conclusion is supported by a dramatic reduction in overall Ab42 levels upon deleting JNK3 from FAD mice. Such a dramatic reduction is not only due to the ability of JNK3 to phosphorylate APP directly, but also due to the cyclic activation of JNK3 by a translational block and subsequent UPR that had been induced by oligomeric Ab42 in the first place. JNK3 phosphorylates APP at the T668P site in its cytoplasmic domain both in vitro and in vivo. The fact that JNK or JNK3 phosphorylates APP is also supported by a study, where double deletion of putative upstream JNK kinases, MKK4 and MKK7, from another FAD mouse line resulted in a reduction in T668P phosphorylation (Mazzitelli et al., 2011) . T668P phosphorylation was increased in AD brains, wherein the b-CTF rather than the full-length APP exhibited increased T668P phosphorylation compared to the control (Lee et al., 2003) . Supporting the notion that T668 phosphorylation contributes to APP processing, T668P to A668P mutation reduced Ab peptide generation in vitro (Lee et al., 2003) . Our data also support this view: When JNK phosphorylated APP at T668P, the amount of CTF increased. This was in part due to the fact that JNK phosphorylation of T668P in APP facilitated rapid internalization of the receptor as indicated by a reduction in the amount of the fulllength APP on the cell surface. Since JNK3 is not the only kinase that phosphorylates APP at T668P in vivo as indicated by our data, and JNK3 can also be activated in the axon under pathological conditions (Falzone et al., 2009; Morfini et al., 2009) , we hypothesize that JNK3 is the predominant kinase that phosphorylates APP within particular endosomal compartments in the axon where APP encounters BACE1 (Abe et al., 2009; Cavalli et al., 2005) .
Structurally, phosphorylation at T668P induces propyl isomerization, converting the p-T668P peptide from trans to cis configuration (Ramelot and Nicholson, 2001 ). Pin1, a phosphorylation-dependent propyl isomerase, indeed binds p-T668P in vitro, thereby facilitating cis to trans conversion (Pastorino et al., 2006) . Since Pin1 deletion from an AD mouse line resulted in a 46% increase in Ab peptide production, cis configuration induced by T668 phosphorylation is believed to render APP vulnerable to amyloidogenic processing (Pastorino et al., 2006) . Our data and those of Lee et al. (2003) also support the idea that T668P phosphorylation is critical for Ab peptide generation in vitro. Whether T668P phosphorylation causes greater Ab peptide generation in vivo is, however, still unresolved. In normal aged mice, A668P knock-in mutation did not affect b CTF generation (Sano et al., 2006) , leading the authors to conclude that T668P phosphorylation plays no role in APP processing. Such a conclusion is premature especially with gain-of-function mutations such as phosphorylation, until the role of T668P phosphorylation is assessed in AD mouse models. A case in point is that although hyperphosphorylation of tau is clearly indicated as pathologic, deleting tau alone showed a relatively minor defect in axon degeneration (Dawson et al., 2001; Gó mez de Barreda et al., 2010; Harada et al., 1994) . It was only when tau was deleted under an AD background that improvement in cognitive behavior was observed (Roberson et al., 2007) . Although critical experiments are still needed to address whether T668P phosphorylation causes APP processing in vivo, our study provides additional support to the idea that T668P phosphorylation significantly contributes to APP processing in vivo. We provide compelling evidence that a translational block is a prominent feature in FAD mice and to some extent in human AD cases. Since oligomeric Ab42 induced a translational block in hippocampal neurons in culture, it is highly likely that oligomeric Ab42 has a similar effect in vivo. Oligomeric Ab42 is widely believed to be the central pathologic species that is responsible for inhibiting LTP and memory formation in vivo (Cleary et al., 2005; Walsh et al., 2002) . Since inhibiting normal translational processes by disabling eif2a phosphorylation or deleting its kinase, GCN2, resulted in inhibition of LTP (Costa-Mattioli et al., 2005 , it is tempting to speculate that such synaptotoxicity observed with oligomeric Ab42 is likely to be due to its inhibitory effect on translation.
Our data indicate that oligomeric Ab42 inhibits translation in part by blocking the mTOR pathway. Dysregulation of the mTOR pathway or loss of energy balance has been identified as causative in normal aging as well as type 2-diabetes and obesity (Cohen et al., 2009; Demontis and Perrimon, 2010; Koo et al., 2005; Mair et al., 2011; Song et al., 2010) . Our findings that widespread disruption of normal energy balance is prominent in FAD mice and to some extent in human AD cases suggest that in progressive diseases whose symptoms develop over a long period time, chronic metabolic imbalance becomes a pervasive phenotype. Our data clearly illustrate that oligomeric Ab42 perturbs energy homeostasis, as indicated by activation of AMPK, a kinase that responds to energy imbalance in the cell (Steinberg and Kemp, 2009) . AMPK was shown to play a critical role in aging in yeast and C. elegans, although the loss of snf1p, the yeast homolog of AMPK, increased the life span (Lin et al., 2001) , while mutation in aak-2, the worm homolog of AMPK, decreased the life extension induced by stress (Apfeld et al., 2004) . Besides this apparent species-related difference in homolog roles, the role of AMPK itself in aging appears clear. It is of special interest in this regard that oligomeric Ab42 activates AMPK, thereby inhibiting the mTOR pathway. Ab peptides are normally produced and cleared rapidly in human brains (Bateman et al., 2006) . It is plausible that normal production of Ab peptides contributes to the aging process in part by activating AMPK.
AMPK activation was rapid but transient by oligomeric Ab42, detectable at 10 min, but greatly reduced by 3 hr after Ab42 addition. Although transiently activated, AMPK substrates Raptor and TSC2 remain phosphorylated up to 16 hr, providing an explanation for a prolonged translational inhibition. What will be the mechanism by which oligomeric Ab42 activates AMPK? AMPK was shown to be activated by LKB1 (Hawley et al., 2003; Shaw et al., 2004) , CaMKK (Anderson et al., 2008; Hawley et al., 2005; Hurley et al., 2005; Woods et al., 2005) , and TAK1 (Momcilovic et al., 2006) . In the nervous system, however, LKB1 does not seem to serve as a kinase for AMPK, since AMPKa phosphorylation at T172 was not changed in LKB1 null mice (Barnes et al., 2007) . A likely candidate is CaMKK, since it is highly expressed in the brain and it associates with AMPK a and b subunits (Anderson et al., 2008) . If that is the case, it is possible that oligomeric Ab42 itself modulates intracellular calcium levels, thereby activating CaMKK. It will be of interest to test whether intracellular calcium levels change with oligomeric Ab42 addition in neurons.
Can mTOR activity modulation be developed into a therapy for AD? This is an attractive idea, since there are already many FDA-approved drugs that were designed to target the mTOR pathways for treating other progressive metabolic diseases. Although attractive, the idea appears too premature at the present time mainly because the role of the mTOR pathway in AD is not fully understood. For instance, some reported improvement in cognitive function and neuronal toxicity with Rapamycin administration (Berger et al., 2006; Bové et al., 2011; Caccamo et al., 2010; Khurana et al., 2006; Spilman et al., 2010) , while others reported the opposite (Lafay-Chebassier et al., 2005) .
Similarly, the reports vary as to whether there is an inhibition or activation of the mTOR pathway in AD mouse models and/or human cases (Caccamo et al., 2011; Ma et al., 2010) . Our data indicate that there is a significant translational block early in FAD mice. This notion was also supported by a global transcriptome analysis via RNaseq, which demonstrated a dramatic reduction in transcripts for ribosomes and elongation factors in FAD compared to the wild-type mice (data not shown). It is possible that the use of different animal models at different ages in each study contributed to the opposite outcomes. It seems safe to surmise that before one takes further steps to alter the mTOR pathway or AMPK activity in pursuit of a treatment for AD, more systematic and consistent analyses are necessary.
In conclusion, our findings suggest that JNK3 activation is central to the development of AD pathology by exacerbating metabolic stress that is induced by Ab42 accumulation. This study thus identifies JNK3 as a promising new target of therapeutic intervention for Alzheimer's disease.
EXPERIMENTAL PROCEDURES Human Samples
Tissues from the frontal cortex were obtained through UCSD Experimental Neuropath Laboratory. . This study was approved by the IACUC of the Ohio State University.
Mouse Breeding
Rat Hippocampal Neuron Cultures
The hippocampal neurons were isolated from E18 rat embryos and cultured for 7 days in Neurobasal medium supplemented with B27 and 2 mM glutamine.
Organotypic Slice Preparations
Organotypic slices 500 mm thick were prepared according to (del Río and Soriano, 2010) from 12-to 14-week-old FAD:JNK +/+ and FAD:JNK3 À/À mice.
JNK3 Immunoprecipitation/Kinase Assays
The lysates from hippocampal neurons were subjected to immunoprecipitation with JNK3 antibody, and the immune complexes were used in kinase reactions using GST-c-jun as a substrate as described (Li et al., 2007) .
Tissue Preparation for Ab40 and 42 Elisa
Brain tissues that contain the cortex, the hippocampus, the septum, and the striatum were used to extract proteins using 70% formic acid.
Preparations of Crude Membrane Fractions
Brain tissues were processed to obtain membrane and soluble fractions for biochemical analyses as described (Pastorino et al., 2006) .
Quantification of Plaque Areas and the Numbers of Neurons
For the quantification of the areas occupied by plaques, two 60 mm floating sections from the bregma positions from +0.26 to +0.5 for the frontal cortex were processed for staining with 6E10 (n = 4).
Silver Staining
Coronal sections of the brains (60 mm) were processed for silver staining using a FD NeuroSilver kit from FD Neurotechnologies as directed by the manufacturer. Rapamycin for the indicated amount of time and the resulting whole-cell lysates were analyzed for 6E10 Western. In order to facilitate detection of CTF and Ab peptides, the slices were also treated with 10 mM MG132 at the same time. Note that both CTF and Ab42 levels were increased in FAD:JNK3 
